iwCLL

1-888-476-9129 info@bioascend.com

Menu
Monday, May 15

Did you miss this year’s iwCLL 2017? Presentations available regarding state-of the-art concepts emerging from clinic-based and laboratory-based research about the pathobiology and treatment of CLL. This information is organized around the development, progression, and evolution of CLL.

To view the presentations from this iwCLL 2017, please click on individual presentations below. To access each day, please select the individual tabs organized by the workshop days.

 

III: PROGRESSION/EVOLUTION OF CLL: MECHANISMS AND THERAPIES

Session 6         Genetic Changes Involved in the Progression and Evolution of CLL
Chairs: Christopher Vakoc and Nicole Lamanna

On the Origin of CLL Evolution
Dan Landau
Presentation
Not Available
Subclonal Architecture Before and After State-of-the-Art Treatment for CLL
Lesley Ann Sutton
Presentation
Not Available
Richter’s Syndrome: Then and Now
Gianluca Gaidano
 view_pres-01
Life after BTKi Relapse: Biology of Disease and New Strategies
John C. Byrd
 Presentation
Not Available

 

Sessions 7A      Additional Therapies for the Relapsed/Refractory CLL Patient
Chairs: Michael Keating and Jacqueline Barrientos

*Durability of Responses on Continuous Therapy and Following Drug Cessation in Deep Responders with Venetoclax and Rituximab
Danielle Brander
Presentation
Not Available
Where Are We With PI3K Isoform Inhibitors in CLL?
Jennifer Brown
 view_pres-01
Anti-CD19 CAR-T Cell Therapy With Defined T-Cell Subsets for Ibrutinib-Refractory CLL
David G. Maloney
 view_pres-01

 

Session 7B        Additional Therapies for the Relapsed/Refractory CLL Patient
Chairs: Guillermo Dighiero and Federico Caligaris-Cappio

*A Novel NF-kB Inhibitor Shows Activity in Richter Syndrome
Tiziana Vaisitti
 Presentation
Not Available
*Allogeneic Hematopoietic Stem Cell Transplantation Using HLA-Compatible Donors in Younger High Cytogenetic Risk CLL Patients Results in Very High Long-Term Progression-Free Survival and May Therefore Favorably Compete With Sequential Targeted Therapy
Michael van Gelder
view_pres-01
*Reduced-Intensity Conditioning Allogeneic Stem Cell Transplantation for High Risk CLL Followed by Preemptive MRD-Based Immunointervention: Final Results From the Phase II ICLL03 RICAC-PMM Trial
Olivier Tournilhac
Presentation
Not Available
Closing comments
Nicholas Chiorazzi
view_pres-01

*Selected Abstract

Please contact us at iwcll2017@bioascend.com for more information.